| Project/Area Number |
18K16585
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56010:Neurosurgery-related
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 慢性脳虚血モデル / 間接血行再建術 / HMGB1蛋白 / VEGF / 血管新生 / 慢性脳虚血 / 間接バイパス術 / HMGB1 / もやもや病 / 脳血流SPECT |
|---|
| Outline of Final Research Achievements |
Moyamoya disease is an intractable disease in which cerebral blood flow is reduced due to progressive stenosis and occlusion of bilateral internal carotid arteries, resulting in cerebral infarction. One of the treatment methods is indirect revascularization, in which muscles are placed on the brain's surface to increase cerebral blood flow. We have focused on HMGB1 protein, an angiogenic factor, as drug therapy to increase cerebral blood flow further.
In the experiment, we occluded bilateral common carotid arteries of rats to reduce cerebral blood flow. We laid the unilateral temporal muscle on the brain surface to create a moyamoya disease surgical model. Furthermore, by administering HMGB1 protein to the temporal muscle used in the surgery, we were able to increase the number of blood vessels in the cerebral cortex and show that cerebral blood flow increased compared to when HMGB1 protein was not administered.
|
| Academic Significance and Societal Importance of the Research Achievements |
もやもや病手術モデルにおける薬物療法は、今までに報告されてきたものは遺伝子を用いたものだけでしたが、今回は蛋白製剤（HMGB1蛋白）を用いることで脳表の血管が増加していることを示すことができ、さらに脳血流評価によってその有効性を示すことができた点が、学術的意義があると考えられる点です。この結果により、もやもや病の間接血行再建術における薬物併用療法が、より臨床応用しやすくなったため、社会的意義があったと考えられます。
|
